Auger Molecular Therapy – clinical indication

Auger Molecular Therapy (AMT) is designed for tumors on or close to the body surface. The current indication approved by US FDA for clinical trial is malignant wound

The IND of Auger Molecular Therapy (AMT) for malignant wound treatment has been approved by US FDA in Sep. 2022 for phase 1 clinical trial

Malignant Wound

  • lMalignant Wound (or Malignant Fungating Wound) occurs in around 5-10% of cancer patients worldwide.
  • lResulting from invasions of solid neoplasm to skin surface that causes open lesion.
  • lFrequently occurs in late stage or recurrence cancer patients, severely interferes with quality of life
  • lNo treatment regimen is designed specifically to combat against MFW. Palliative care is the main option with goals of symptom control and improving quality of life for patients.

References

Project Schedule

Project schedule

Research Process

Malignant Fungating Wound

  • Malignant Fungating Wound (MFW) occurs in around 5-10% of cancer patients worldwide.
  • MFW is originated from invasion of solid neoplasm to skin surface causing open lesion.
  • Usually occurs in late stage or recurrence cancer patients.
  • No treatment regimen is designed specifically to combat against MFW.
  • Palliative treatment  is the only option with goals of symptom control and improving quality of life for patients.

Project schedule

Research Process

Potential Market Size

  • New cases of cancer worldwide: 18.1 million patients / year
  • Malignant fungating wound prevalence: 5% of cancer patients
  • Potential malignant wound cases worldwide: 905,000 patients / yr

References